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Summary Sequential biopsies of breast cancer tissue were obtained from a total of 210 women in order to
assess any change in oestrogen receptor (ER) status arising spontaneously or as a result of intervening
therapy. A combined assay measuring both cytosol and nuclear oestrogen receptors was used for all samples.
One hundred and fifty-five patients had biopsies of their primary tumour and of a later loco-regional
recurrence; 26 had biopsies of their primary tumour and a recurrence or new primary in the opposite breast;
and 29 had sequential biopsies of recurrent disease only. Overall only 61.2% of the primary tumours retained
their original status with respect to both cytosol and nuclear oestrogen receptors on recurrence. These results
were influenced by intervening therapy, however, and if only untreated patients are considered, over 70% of
their recurrences contain the same combination of cytosol and nuclear receptors as found in the primary
tumours. For tumours 'recurring' in the opposite breast, the pattern was similar with 69.2% retaining the
same status as the first primary. The agent found most likely to alter ER status was tamoxifen and in the
samples taken from patients undergoing treatment with this drug, no tumour was found to contain
measurable receptor.
Oestrogen receptor (ER) status has become firmly estab-
lished as a useful predictor of hormone dependence in
human breast cancer (McGuire et al., 1975). In practice,
however, at least one-third of patients who develop recurrent
disease after excision of a receptor-positive primary breast
cancer will fail to respond to endocrine therapy. One
possible explanation for this would be variation in ER status
between the primary and metastatic disease. As for many
patients the primary tumour represents the only readily
accessible source of tissue for ER analysis, it is important to
establish to what extent the ER status of metastatic tumours
differs from the ER status of the primary from which they
originated.
We know from previous studies that the ER status of
primary breast tumours can predict the response of recurrent
disease to endocrine therapy (Campbell et al., 1981; Harland
et al., 1983). The extent to which ER status can change from
one biopsy to another has also been previously studied with
varying results (see Discussion). Hormone dependence in
breast cancer can be predicted more accurately by using a
combination of cytosol and nuclear oestrogen receptors than
by cytosol ER alone (Leake et al., 1979). In this study we
have measured both cytosol and nuclear oestrogen receptors
in sequential biopsies of primary and recurrent breast
cancers.
Following mastectomy, many patients now receive
systemic adjuvant treatment usually in the form of cytotoxic
chemotherapy or endocrine therapy (usually tamoxifen). We
have therefore also assessed the effects of any intervening
therapy on the ER status of their recurrent disease. In
addition we have examined the receptor status of tumours
arising in the contralateral breast in relation to the initial
disease.
Patients and Methods
Treatnment groups
A total of 210 patients with proven breast cancer underwent
sequential biopsies of their breast cancers for ER assay, with
at least 6 months between the first and second biopsies.
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One hundred and fifty-five patients had ER assays per-
formed on a sample from their primary tumour and from a
subsequent loco-regional recurrence. These 155 patients can
be subdivided into three groups:
(a) 94 patients wtho received no ssystemic anti-tumour
therapy in the period between their first and second biopsies.
(b) 29 patients wvho received adjuvant chemotherapj (CMF)
for one year post-mastectomy. Of these, 24 had completed
their course of therapy prior to developing their recurrence,
leaving 5 patients still on CMF at the time of their second
biopsy.
(c) 32 patients who received endocrine therapy between
their first and second biopsies. Twenty-one were given this
on an adjuvant basis (20 received tamoxifen 20mg daily for
either 2 or 5 years post-mastectomy and a single patient
underwent oophorectomy followed by prednisolone).
Eighteen of these 21 patients were still receiving adjuvant
endocrine therapy when their recurrence developed. The
remaining 11 patients in this group were receiving tamoxifen
on a therapeutic basis for metastatic disease at the time of
their second biopsy.
Twenty-six patients had oestrogen receptor assays per-
formed on their primary tumours and on a subsequent
recurrence (or new primary) in the contralateral breast.
Twenty of these patients received no systemic therapy
between their biopsies.
A further group of 29 patients whose primary ER status
had not been measured underwent sequential biopsies of
recurrent disease. As a separate analysis the results from
these patients were grouped along with those of 28 women
from the 155 described above, who in addition to their
primary and first recurrence also had biopsies of a later
second recurrence. This gives a total group of 57 women
who have been assessed on the basis of sequential biopsies of
recurrent tumours.
The majority of this last group of patients had reached a
fairly advanced stage in their disease, by which time most of
them had received at least one systemic treatment modality.
These patients and the groups receiving adjuvant therapy
have been assessed mainly with regard to the effects of
therapy on oestrogen receptor status. Because the clinical
data were reviewed retrospectively, it has not been feasible to
objectively assess subsequent clinical response to endocrine
therapy in the majority of patients.
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Assays
Samples for ER assays were taken from primary tumour
biopsies prior to frozen section or from the fresh mastectomy
specimen and from biopsies of recurrent tumours immedi-
ately following excision. Histological confirmation of the
presence of breast carcinoma in the remainder of the biopsy
has been obtained for all samples studied. The majority of
the samples were stored and transported at -20°C in
sucrose-glycerol buffer (Crawford et al., 1984) prior to assay.
Concentrations of both soluble (cytosol) and nuclear
oestrogen receptors were measured using an established 7-
point competition (± 100 fold DES) assay (Love et al.,
1983).
Assay criteria were as previously defined and receptor
concentration was calculated by Scatchard analysis (Leake et
al., 1981). Protein content of the cytosol and DNA content
of the nuclear pellet were measured by the methods of
Lowry (1951) and Burton (as modified by Katzenellenbogen
& Leake, 1974) respectively. Results were expressed in
fmol mg 1 cytosol protein and fmol mg 1 DNA.
Results
Depending on the presence or absence of oestrogen receptor
in each cell fraction (Cytosol/Nuclear), four patterns of
receptor distribution are theoretically possible. The majority
of tumours are found to have either receptor in both cytosol
and nuclear fractions (designated +/+), or to totally lack
receptor, designated (0/0). A small proportion of tumours
have receptor in one fraction only, i.e. +/0 where receptor is
present in the cytosol but not the nuclear fraction; or vice
versa 0/+. These latter two groups represent tumours which
are referred to as containing abnormal or incomplete
receptor and, in previous studies, these tumours have been
found not to be hormone dependent in behaviour (Cowan et
al., 1984). Results in each of the groups detailed below will
be described in terms of the number of tumours falling into
each of these four receptor categories at the time of their
initial biopsy and again at the time of the subsequent
recurrence.
1. Allpatients with biopsies oftheir primary tumour andfirst
loco-regional recurrence
Table I shows the results for all 155 patients with biopsies of
their primary cancer (first assay) and first loco-regional
recurrence (second assay). Overall 95 (61.2%) of these 155
tumours retained their original status with respect to cytosol
and nuclear ER. There is an apparent trend for +/+
tumours to 'lose' receptor with time. Only 39 (60.4%) of the
64 +/+ tumours retained their original ER status, while 56
(83%) of the 0/0 tumours remained 0/0 on recurrence.
None of the +/0 or 0/+ tumours retained their original
status, perhaps indicating that these receptor categories
represent tumours in a transitional state. These changes have
been further analysed below by subdividing the patients into
various treatment categories.
Table I ER status of 155 primary breast carcinomas
compared with the ER status of their first loco-regional
recurrence
Second assay
First assay No. ofpatients in each category
ER status No. +/+ 0/0 +/0 0/+
2a. Patients with no systemic therapy between their biopsy of
primary tumour and biopsy offirst loco-regional
recurrence
Table Ila shows that in the absence of intervening therapy,
fewer +/+ tumours appear to have lost receptor on re-
currence, with 33 (80.4%) of 41 +/+ tumours remaining
+/ +. Overall in this untreated group, 66 (70.2%) of 94
tumours retained their original ER status and if the
incomplete or abnormal categories (+/0 and 0/+) are
excluded and only +/+ and 0/0 primary tumours
considered, 81.5% have the same status on recurrence.
2b. Adjuvant chemotherapy
There was considerable variation in ER status between the
primary and recurrent tumours in this subgroup (Table lIb).
Only 15 (51.7%) of these 29 patients retained their original
ER status on recurrence. However although only half the
ER +/+ tumours remained +/+, several tumours in other
categories 'gained' receptor. Overall therefore the distri-
bution of ER status in the recurrences is almost identical to
that in the primary tumours.
2c. Endocrine therapy
The results from this subgroup of 32 patients (Table Tlc)
show a convincing trend for ER+/+ tumours to become
negative following treatment with tamoxifen. Only one of 13
+/ + tumours remained +/+, this recurrence developing 20
months after the cessation of adjuvant tamoxifen therapy.
This group accounts almost entirely for the difference in
receptor variation between the results in Table I and Table
Ila.
Table II The effect of intervening therapy on the ER status
of patients with biopsies of their primary tumour (first assay)
and first loco-regional recurrence (second assay)
Second assay
First assay No. ofpatients in each category
ER status No. +/+ 0/0 +/0 0/+
(a) With no intervening therapy
+/+ 41 33 8 0 0
0/0 40 6 33 1 0
+/0 10 2 5 0 3
0/+ 3 1 1 1 0
Total 94 42 47 2 3
(b) Adjuvant chemotherapy
+/+ 10 5 2 2 1
0/0 13 1 10 0 2
+/0 4 1 1 0 2
0/+ 2 2 0 0 0
Total 29 9 13 2 5
(c) Endocrine therapy
+/+ 13 1 12 0 0
0/0 14 1 13 0 0
+/0 3 0 3 0 0
0/+ 2 1 0 1 0
Total 32 3 28 1 0
3. Patients with biopsies from their primary tumour and a
recurrence in the contralateral breast
As shown in Table III, the extent of receptor variation
between the first and second tumours is no greater than is
seen in the main group of loco-regional recurrences. Six of
these women had received intervening adjuvant therapy (5
tamoxifen and 1 CMF) but this did not influence the results
as 4 were initially 0/0 (3 remained 0/0 and 1 changed to
+/+) and 2 were initially 0/+.
+/+ 64 39 22 2 1
0/0 67 8 56 1 2
+/0 17 3 9 0 5
0/+ 7 4 1 2 0
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Table III ER status of sequential biopsies from primary
breast tumours and recurrences developing in the
contralateral breast
Second assay
First assay No. ofpatients in each category
ER status No. +/+ 0/0 +/0 0/+
+/+ 10 8 1 0 1
0/0 14 4 10 0 0
+/0 0 0 0 0 0
0/+ 2 1 1 0 0
Total 26 13 12 0 1
4. Changes in ER status in sequential biopsies ofrecurrent
disease
The pooled results from these 57 patients are shown in Table
IV. Only 34 (59.9%) of them retained their original ER
status on recurrence. Of the 19 +/+ tumours, 8 apparently
lost receptor, becoming 0/0. Six of these 8 were receiving
tamoxifen at the time of their second biopsy, one had just
stopped CMF and only one had no intervening systemic
therapy. None of the 11 who remained +/+ had received
systemic treatment (7 had their first recurrence treated by
excision alone and 4 by excision plus radiotherapy).
Thirty-one of these tumours were 0/0 on first recurrence
and the majority, 23 (74.2%) remained 0/0. Three of the 7
who changed to +/ + were known to have been taking
tamoxifen at the time of their first recurrence and had
stopped this treatment by the time the second recurrence was
biopsied. As with the primary tumours, none of the tumours
whose first recurrence contained abnormal or incomplete
receptor (+/0 and 0/+) retained this status on second
recurrence (even those who had received no intervening
therapy).
Table IV ER status of sequential biopsies from patients with
recurrent disease (i.e. all patients with assays on a recurrence
followed by a further recurrence)
Second assay of recurrence
First assay ofrecurrence No. ofpatients in each category
ER status No. +/+ 0/0 +/0 0/+
+/+ 19 11 8 0 0
0/0 31 7 23 1 0
+/0 4 0 4 0 0
0/ + 3 3 0 0 0
Total 57 21 35 1 0
Discussion
Several previous studies have shown conflicting data on the
stability of cytosol ER status (Rosen et al., 1977; Allegra et
al., 1980; Peetz et al., 1982; Holdaway & Bowditch, 1983)
but all of these studies were performed on relatively small
numbers of patients. A number of more recent studies have
also examined progesterone receptors in addition to cytosol
ER in multiple tumour samples from individual patients
(Harland et al., 1983; Raemakers et al., 1984; Nomura et al.,
1985) but none of these considered nuclear ER data. We
have re-examined this question in terms of both cytosol and
nuclear oestrogen receptors. While our data confirm that
changes in ER status occur, the number of tumours
changing spontaneously is small and in the absence of
intervening therapy, cytosol and nuclear ER status is
relatively stable.
The majority of tumours converting, particularly from
ER-positive to ER-negative, have done so under the in-
fluence of systemic therapy. Tamoxifen appears to be the
most consistent in this respect and, in this series, no tumour
was found to have measurable oestrogen receptors if the
patient was receiving tamoxifen at the time of biopsy. The
precise mechanism of this action is unclear (Taylor et al.,
1982; Toma et al., 1985). It may be simply that tamoxifen
blocks the biochemical assay by competing with the radio-
labelled oestradiol preventing it from binding to the receptor.
Alternatively, in the longer term, it may be that tamoxifen
interferes with receptor synthesis. Studies using monoclonal
antibodies to oestrogen receptor for radioimmunoassay or
histochemical staining may shortly resolve this point, though
at present the expense of these antibodies is such that they
are unlikely to be introduced widely for routine assays.
Both histochemical (King et al., 1985) and biochemical
(Silfversward et al., 1980; Poulsen et al., 1981) studies have
shown considerable heterogeneity of oestrogen receptor
distribution within breast tumours. An ER-positive tumour
may therefore contain a significant population of ER-
negative cells. It has therefore also been suggested that
tamoxifen may selectively destroy ER-positive cells, leaving
ER-negative cells to predominate in any subsequent re-
currence. From our observations on sequential biopsies of
recurrent disease however, we know that at least some
tumours regain ER function after stopping treatment.
The effect of adjuvant chemotherapy on ER status is less
well defined. Although a relatively high proportion of these
tumours changed their status on recurrence, as many
tumours appear to have gained ER as have lost ER, leaving
the overall distribution of ER status in this group virtually
unaltered on recurrence. There is no general agreement as to
whether a recurrence in the opposite breast represents a true
recurrence or a second primary'tumour. The fact that 4 0/0
tumours out of 14 (see Table III) changed to +/+ on
recurrence suggests that at least some of these tumours were
new primaries rather than recurrences of the original
tumour.
A further factor potentially influencing changes in ER
status is the quality of the assay itself. All assays used in this
study were subject to internal quality control and our
laboratory actively participates in external quality control,
through the EORTC receptor group (Koenders & Thorpe,
1983). The assay used in this laboratory and criteria for
determining receptor concentration were established over ten
years ago (Laing et al., 1976). All the samples in this study
fulfil these criteria and we therefore feel that experimental
error has not significantly contributed to the changes in ER
status observed.
Despite having histological evidence of breast cancer in all
the tumours assayed, a number of samples of 'unexpected'
negative ER results occurred in samples with very low DNA
levels. This problem is particularly relevant with cutaneous
local recurrences, where the proportion of the sample com-
posed of tumour cells may be very small. Although we do
not set a lower limit for acceptable DNA level we routinely
include the tumour DNA concentration in our reports to
clinicians and comment if this is low. The introduction of
immunohistochemical methods of localising oestrogen
receptor should help to identify some of these ER-positive
tumours of low cellularity (King et al., 1985).
We conclude that in the absence of intervening systemic
therapy, ER status of breast tumours is relatively stable and
the ER status of an adequate sample from the primary
tumour should predict the likelihood of response to endo-
crine therapy when the tumour recurs.140 D.J. CRAWFORD et al.
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